⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL29261893 | 0.91 | LMNA (0.50) | — | |
| SCHEMBL29728513 | 0.83 | LMNA (0.58) | — | |
| SCHEMBL17797345 | 0.81 | — | — | |
| SCHEMBL7354254 | 0.81 | — | — | |
| SCHEMBL7354257 | 0.81 | — | — | |
| SCHEMBL25132600 | 0.79 | — | — | |
| SCHEMBL22012650 | 0.79 | — | — | |
| SCHEMBL23175047 | 0.79 | — | — | |
| SCHEMBL1702283 | 0.79 | — | — | |
| SCHEMBL28105057 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1906945-B1 | HCV INHIBITORS | VIROBAY INC (US) | 2015-08-05 | — | — | EP | claimed |
| EP-2431379-A2 | HCV inhibitors | Virobay, Inc. (US) | 2012-03-21 | — | — | EP | claimed |
| US-20100266537-A1 | HCV INHIBITORS | VIROBAY, INC. (US) | 2010-10-21 | — | — | US | claimed |
| US-7608592-B2 | HCV inhibitors | VIROBAY, INC. (US) | 2009-10-27 | — | — | US | claimed |
| EP-1906945-A4 | HCV INHIBITORS | VIROBAY INC (US) | 2009-07-15 | — | — | EP | claimed |
| WO-2008086053-A1 | HCV INHIBITORS | VIROBAY, INC. (US) | 2008-07-17 | — | — | WO | claimed |
| US-20080161254-A1 | HCV INHIBITORS | VIROBAY, INC. (US) | 2008-07-03 | — | — | US | claimed |
| EP-1906945-A2 | HCV INHIBITORS | Virobay, Inc. (US) | 2008-04-09 | — | — | EP | claimed |
| US-20070054864-A1 | 1-[2S-(3-Tert-butylureido)-3,3-dimethylbutyryl]-4R-(7-methoxy-2-pyrazol-1-yl-quinolin-4-yloxy)-pyrrolidine-2S-carboxylic acid (1S-cyclopropylaminooxalylbutyl)amide, for example; useful in treating hepatitis C infections | QUEST DIAGNOSTICS INVESTMENTS LLC | 2007-03-08 | — | — | US | claimed |
| WO-2007005838-A2 | HCV INHIBITORS | VIROBAY, INC. (US) | 2007-01-11 | — | — | WO | claimed |
| US-6410778-B1 | — | — | None | — | — | US | disclosed |
| CN-113272298-B | Compounds and compositions for the treatment of respiratory diseases | 天莅生物技术有限公司 | 2025-04-18 | — | — | CN | disclosed |
| WO-2024096066-A1 | CYCLIC PEPTIDE DERIVATIVE COMPOSITION FOR TREATING OR PREVENTING CENTRAL NERVOUS SYSTEM INJURY/DISEASE | 第一工業製薬株式会社 | 2024-05-10 | — | — | WO | disclosed |
| WO-2024096067-A1 | CYCLIC PEPTIDE DERIVATIVE COMPOSITION FOR TREATING OR PREVENTING NEUROPATHIC PAIN AND/OR INFLAMMATORY PAIN | 第一工業製薬株式会社 | 2024-05-10 | — | — | WO | disclosed |
| WO-2024094637-A1 | PROCESS FOR THE PREPARATION OF CYCLIC KETONES | ARXADA AG (CH) | 2024-05-10 | — | — | WO | disclosed |
| US-4497963-A | ETHYLENICALLY UNSATURADED POLYMERS | BASF AKTIENGESELLSCHAFT (DE) | 1985-02-05 | — | — | US | disclosed |
| US-4375000-A | Process for the preparation of an aryl mono-, di-, and/or polyurethane | BASF AKTIENGESELLSCHAFT (DE) | 1983-02-22 | — | — | US | disclosed |
| US-4349484-A | Process for the manufacture of mixtures of diphenylmethane diisocyanates and polyphenyl polymethylene polyisocyanates | BASF AKTIENGESELLSCHAFT (DE) | 1982-09-14 | — | — | US | disclosed |
| US-4290970-A | Process for the manufacture of aromatic di- and/or polyisocyanates | BASF AKTIENGESELLSCHAFT (DE) | 1981-09-22 | — | — | US | disclosed |
| US-4278805-A | FROM AROMATIC AMINE, CARBAMATE AND ALCOHOL; METAL COMPOUND CATALYST | BASF AKTIENGESELLSCHAFT (DE) | 1981-07-14 | — | — | US | disclosed |